The buildup of a protein called 𝛂-synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson's and multiple system atrophy (MSA). These aggregates are associated with cellular dysfunction and lead to progressive neuronal loss. Because current treatments only manage symptoms rather than stopping the underlying protein clumping, scientists are exploring new strategies, including nanomaterials that can prevent these aggregates from forming or help clear them from the brain.